Hospital Acquired Disease Testing Market Size Worth US$ 7.14 Billion by 2030 at 7.7% CAGR, COVID-19 Impact and Global Analysis by Growth Plus Reports

NEW YORK, Sept. 16, 2022 /PRNewswire/ -- According to the latest report published by growth plus reports, the global hospital acquired disease testing market is expected to clock US$ 7.14 billion by 2030 and to grow at a CAGR of 7.7% during the forecast period. Owing to the Increasing incidence of hospital acquired infections and Increasing launches of advanced and efficient testing tools and kits are key driving factors. this exclusive information is published by Growth Plus Reports in its report titled "Hospital Acquired Disease Testing Market – Global Outlook & Forecast 2022-2030"

Market Driver

The number of medical facilities has significantly increased as a result of the growing global population, rapid urbanisation, and modernization of the healthcare infrastructure. The incidence of HAIs has increased as a result, which is driving up demand for hospital acquired diseases testing market. The market is also predicted to rise as a result of the expanding use of cutting-edge technologies, including as solid phase hybridization, polymerase chain reaction (PCR), microarrays, and real-time location systems (RTLSs), for preventing, diagnosing, and monitoring HAIs. However, despite these factors, the market is not without constraints and is challenged by global disparities. The development of the global market is hampered by the lack of standards and limited knowledge of hospital acquired disease testing in third-world countries.

Get a Sample PDF Brochure: https://growthplusreports.com/inquiry/request-sample/hospital-acquired-disease-testing-market/7807

Report Scope & Segmentation:

Excerpts from 'Competitive Landscape'

Some of the prominent market players in the global hospital acquired disease testing market include:

• Abbott Laboratories
• Bayer AG
• Becton Dickinson & Company
• Danaher Corporation
• Sotera Health Company
• Ecolab
• Hologic
• Johnson & Johnson Pvt. Ltd
• Getinge AB
• Merck Kgaa
• Pfizer Inc
• Advanced Sterilization Products (ASP)
• Steris PLC
• Pal International
• Continental Equipment Company
• BGS Beta-Gamma-Service GmbH & Co. KG
• C.B.M. S.r.l
• Continental Equipment Company
• Medizintechnik GmbH & Co. KG
• Reckitt Benckiser

To increase their revenue share, the top players in the market for hospital acquired disease testing are utilising a variety of methods, such as R&D investments, the use of cutting-edge techniques, mergers and acquisitions, and geographical development. Furthermore, manufacturers are concentrating on developing improved testing kits. For instance, in December 2019, Cobas vivoDx MRSA, a diagnostic test designed to identify Methicillin-resistant Staphylococcus aureus (MRSA) bacteria, has been approved by the U.S. Food and Drug Administration (FDA). Cobas vivoDx MRSA's certification is meant to help manage and prevent Methicillin-resistant Staphylococcus aureus (MRSA) infections in healthcare facilities.

Excerpts from 'By Infection Type Segmentation'

Based on type, the global hospital acquired disease testing market has been segmented into:

• Hospital Acquired Pneumonia
• Bloodstream Infections
• Surgical Site Infections
• Gastrointestinal Infections
• Urinary Tract Infections (Uti)

During the predicted period, the urinary tract infection segment accounted for a largest revenue share with a profitable CAGR. This is as a result of the fact that UTIs are the most prevalent disease acquired in hospitals worldwide. However, during the projection period, the surgical site infection segment is anticipated to expand at a profitable CAGR. This is a result of hospital staff members' negligence while the patient was there.

Inquiry Before Buying: https://growthplusreports.com/inquiry/before-buying/hospital-acquired-disease-testing-market/7807

Excerpts from 'By Region Segmentation'

Based on the region, the global hospital-acquired disease testing market has been segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the World

The largest share of the global market for hospital acquired disease testing was held by North America. The expanding emphasis on healthy lifestyles and disease prevention among consumers is what characterizes market growth in this region. One of the main factors driving the expansion of the hospital acquired disease testing market in North America is the rising number of HAI-related deaths each year in the United States. The rules put in place by governments and other organisations, along with the increased need for diagnostics, will all contribute to the market's expansion in America. However, Asia Pacific is predicted to experience the market's fastest growth rate for tests for hospital acquired diseases. The rise in nosocomial infections and the accompanying enactment of more stringent rules to reduce HAIs are factors contributing to the market expansion in Asia Pacific. Additionally, escalating investments in healthcare infrastructure will benefit the region's market for hospital acquired disease diagnostics.

1. INTRODUCTION
1. Market Ecosystem 
2. Timeline Under Consideration
1. Historical Years – 2020
2.  Base Year – 2021
3.  Forecasted Years – 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources 
2. Primary Sources 
4. Market Estimation Approach
1. Bottom Up 
2. Top Down 
5. Market Forecasting Model
6. Limitations and Assumptions 
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021) 
4. MARKET DYNAMICS
1. Drivers
2. Restraints/Challenges
3. Opportunities
5. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET - ANALYSIS & FORECAST, BY PRODUCT
1. Instruments
2.  Reagents
3.  Consumables
6. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET - ANALYSIS & FORECAST, BY TEST TYPE
1. Molecular Diagnostics
2. Immunoassay
3. Others
7. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET - ANALYSIS & FORECAST, BY APPLICATION
1. Disease Testing
2. Drug-Resistance Testing
8. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET - ANALYSIS & FORECAST, BY INFECTION TYPE
1. Hospital Acquired Pneumonia
2. Bloodstream Infections
3. Surgical Site Infections
4. Gastrointestinal Infections
5.  Urinary Tract Infections
9. GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET - ANALYSIS & FORECAST, BY END USER
1. Hospital
2. Standalone Laboratories
3. Others

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Directly Purchase Premium Copy of Hospital Acquired Disease Testing Market Growth Report (2022-2030) At: https://growthplusreports.com/checkout?_token=QQ7ydDTWwKKwEUeThZ9ZyOX8qVVBFjL7EySv94ES&report_id=7807&license=Single

About Us:

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

Contact:

Manan Sethi 
Director, Market Insights
Email: enquire@growthplusreports.com
Phone no: +91 96545 76783
Web: https://growthplusreports.com/ 
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/1671244/Growth_Plus_Reports_Logo.jpg